David P. Astling

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

K E Ware, Trista K. Hinz, Emily K. Kleczko et al. · Oncogenesis · 2013 · 255 citations · Full text

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

Stephen B. Keysar, David P. Astling, Ryan T. Anderson et al. · Molecular Oncology · 2013 · 164 citations · Full text

High-efficiency RNA-based reprogramming of human primary fibroblasts

Igor Kogut, Sandra M. McCarthy, M. Pavlova et al. · Nature Communications · 2018 · 160 citations · Full text

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

Kurtis D. Davies, Sakshi Mahale, David P. Astling et al. · PLoS ONE · 2013 · 135 citations · Full text

Small Molecule Inhibitors, Systems Biology, Oncogenic Agent +14

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer

John J. Morton, Gregory H. Bird, Stephen B. Keysar et al. · Oncogene · 2015 · 126 citations · Full text

Tumor Biology, Neck Cancer, Medicine +10